Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II

International Journal of Gynecology and Obstetrics

Volumn 56, Issue 2, 1997, Pages 147-153

  Kodama, S ^a   Tanaka, K ^a   Tokunaga, A ^b   Sudo, N ^c   Takahashi, T ^d   Matsui, K ^e  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA CITY GENERAL HOSPITAL   (Japan)

^c NAGAOKA RED CROSS HOSPITAL   (Japan)

^d Niigata Cancer Center   (Japan)

^e Kashiwazaki Pub Hlth Ctr N P   (Japan)

Author keywords

Multivariate analysis; Ovarian cancer; Prognostic factor

Indexed keywords

ARTICLE; ASCITES FLUID CYTOLOGY; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RUPTURE; SURGICAL TECHNIQUE;

EID: 0031081612     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(96)02798-1     Document Type: Article

References (19)

1. [1] DiSaia PJ, Creasman WT. The adnexal mass and early ovarian cancer. In: DiSaia PJ, Creasman WT, editors, Clinical Gynecologic Oncology, St. Louis: C.V. Mosby. 1993: 300-332.
2. [2] Annual Report on the Results of Treatment in Gynecologic Cancer. Vol. 20. Petterson F, editor. Stockholm: International Federation of Gynecology and Obstetrics. 1988.
3. [3] Purola E, Nieminen U. Does rupture of cystic carcinoma during operation influence the prognosis? Ann Chir Gynecol Fenn 1968; 57: 615-617.
4. [4] Webb MJ, Decker DG, Mussey E, Williams TJ. Factors influencing survival in stage I ovarian cancer. Am J Obstet Gynecol 1973; 116: 222-228.
5. [5] Wiliams TJ, Symmonds RE, Litwak O. Management of unilateral and encapsulated ovarian cancer in young women. Gynecol Oncol 1973; 1: 143-148.
6. [6] Decker DG, Webb MJ, Holbrook MA. Radiogold treatment of epithelial cancer of the ovary: late results. Am J Obstet Gynecol 1973; 115: 751-758.
7. [7] de la Cuesta RS, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84: 1-7.
8. [8] Grogan RH. Accidental rupture of malignant ovarian cyst during surgical removal. Obstet Gynecol 1967; 30: 716-720.
9. [9] Munnel EW. The changing prognosis and treatment in cancer of the ovary: a report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol 1968; 100: 790-805.
10. [10] Parker RT, Parker CH, Wilbanks GD. Cancer of the ovary. Am J Obstet Gynecol 1970; 108: 878-888.
11. [11] Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant ovarian tumors. Gynecol Oncol 1983; 15: 370-380.
12. [12] Sevelda P, Dittrich C, Salzer H. Prognostic value of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol 1989; 35: 321-322.
13. [13] Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-273.
14. [14] Finn CB, Luesly DM, Buxton EJ, Blackledge GR, Kelly K, Dunn JA, Wilson S. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynecol 1992; 99: 54-58.
15. [15] Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours (International histological classification of tumors no. 9). Geneva: World Health Organization. 1973; 37-42.
16. [16] Truett J, Cornfield J, Kannel WB. Multivariate analysis of the risk for coronary heart disease in Framingham. J Chron Dis 1967; 20: 511-524.
17. [17] Shigenobu A. Reference Manual of Medical Statistic Analysis. Tokyo: Egakushoin. 1989; 208-215.
18. [18] Dottino PR, Plaxe SC, Cohen CJ. A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol 1991; 43: 203-205.
19. [19] Piver MS, Malfetano J, Baker TR, Hempling RE. Five year survival for stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992; 46: 357-360.